|CrossRef Text and Data Mining|
|Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.|
|Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?|
|Yun Bin Lee, Jeong-Hoon Lee|
|Clin Mol Hepatol. 2017;23(3):219-221. Published online 2017 September 19 DOI: https://doi.org/10.3350/cmh.2017.0045|
Is tenofovir monotherapy a sufficient defense line against multi-drug resistant hepatitis B virus?
495 Tenofovir (TNV) has stronger antiviral effect than adefovir dipivoxil (ADV) against lamivudine (LAM) resistant hepatitis B virus (HBV)
HBV3 O-29: A randomized comparative open label trial of tenofovir monotherapy versus tenofovir plus telbuvidine dual therapy in spontaneous reactivation of hepatitis B (NCT01732224)
P062: A randomized comparative open label trial of tenofovir monotherapy versus tenofovir plus telbuvidine dual therapy in spontaneous reactivation of hepatitis B (NCT01732224)
Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis
Long-Term Efficacy of Tenofovir Monotherapy for Hepatitis B Virus-Monoinfected Patients After Failure of Nucleoside/Nucleotide Analogues
Detection of Antiviral Drug-Resistant Variants in Chronic Hepatitis C by Deep Sequencing
Good science behind hepatitis C virus antiviral drug development: Necessary but not sufficient
Switching Tenofovir Disoproxil Fumarate (TDF) plus Entecavir Combination Therapy to TDF Monotherapy is Safe and Efficacious in Patients with Multiple Drug-resistant Chronic Hepatitis B: Randomized Trial
ChemInform Abstract: Antiviral Activity of Novel 2′-Fluoro-6′-methylene-carbocyclic Adenosine Against Wild-Type and Drug-Resistant Hepatitis B Virus Mutants.
|This metadata service is kindly provided by CrossRef from May 29, 2014. Clin Mol Hepatol has participated in CrossRef Text and Data Mining service since March 1, 2015.|